Skip to Content

BioGaia AB Class B BGAIF

Rating as of

Morningstar’s Analysis

Valuation
Currency in
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

BioGaia AB is a healthcare company. It develops, markets and sells probiotic products. The company segmented its operating activities into three reportable segments, Pediatrics, Adult Health, and other. Pediatrics segment comprised of digestive health tablets, oral rehydration solution, and cultures as an ingredient in a licensee's product and royalties from pediatric health products. Adult Health business unit comprises digestive health tablets, oral health lozenges, cultures as an ingredient in a licensee's dairy products. The other segment consists of royalties in respect of development projects and animal health products. Its primary geographic markets are Europe, USA and Canada, Asia, and Rest of World.

Contact
Kungsbroplan 3, Box 3242
Stockholm, 112 27, Sweden
T +46 855529300
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 160